Novavax COVID-19 Vaccine Shows Lower Reactogenicity Than mRNA
As COVID-19 seasonal surges continue into 2025, vaccine options have expanded to accommodate varying public health needs and individual preferences. Among these, the Novavax COVID-19 Vaccine, Adjuvanted (2024–2025 Formula), has emerged as a notable alternative to mRNA vaccines, offering comparable protection with potentially fewer side effects. Novavax COVID-19 Vaccine
Rapid tests remain a vital tool in the medicine cabinet for ongoing infection cycles of COVID-19. Be sure to stay stocked up with market-leading ASSURE-100 rapid tests this season.
Understanding Reactogenicity
Reactogenicity refers to the physical manifestations of the inflammatory response to vaccination, such as pain at the injection site, fatigue, or fever. While these symptoms are generally mild and transient, they can influence public perception and willingness to receive vaccines.Verywell Health
SHIELD-Utah Study Findings
A recent study, known as SHIELD-Utah, evaluated the reactogenicity of the Novavax vaccine compared to the Pfizer-BioNTech mRNA vaccine. The study found that recipients of the Novavax vaccine experienced fewer and less severe side effects. Specifically, there was a 12.5% absolute reduction in local reactogenicity events among Novavax recipients. Additionally, the impact on daily activities was lower, with Novavax recipients reporting fewer hours of reduced activity and missed work compared to those who received the mRNA vaccine. The Herald Journal
Vaccine Composition and Authorization
The Novavax vaccine utilizes a protein-based platform, delivering a recombinant spike protein of SARS-CoV-2 combined with an adjuvant to enhance the immune response. This approach differs from mRNA vaccines, which use genetic instructions to prompt cells to produce the spike protein internally.
As of August 2024, the U.S. Food and Drug Administration (FDA) authorized the Novavax COVID-19 Vaccine, Adjuvanted (2024–2025 Formula) for emergency use in individuals aged 12 and older. This formulation targets the Omicron variant JN.1 strain of SARS-CoV-2. Novavax
Dosing Recommendations
According to the Centers for Disease Control and Prevention (CDC), individuals who have never received any COVID-19 vaccine and opt for Novavax should receive two doses of the 2024–2025 Novavax COVID-19 vaccine to be considered up to date. Those who have previously received a different COVID-19 vaccine may require a single dose of the Novavax vaccine, depending on their vaccination history. CDC
Rapid Testing Options
In addition to vaccination, rapid testing remains a crucial tool in managing the spread of COVID-19. For convenient at-home testing, the ASSURE-100 Rapid COVID-19 Home Test offers reliable results, aiding individuals in making informed health decisions.
The Novavax COVID-19 vaccine presents a promising alternative for those seeking a non-mRNA option with a potentially lower side effect profile. As research continues to evolve, staying informed about vaccine options and public health recommendations remains essential in the ongoing fight against the COVID-19 pandemic.
Rapid tests remain a vital tool in the medicine cabinet for ongoing infection cycles of COVID-19. Be sure to stay stocked up with market-leading ASSURE-100 rapid tests this season.
Keywords: COVID-19, Novavax, vaccine, SARS-CoV-2, pandemic, public health, rapid testing, mRNA vaccines, reactogenicity, ASSURE-100 Rapid COVID-19 Home Test